Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Highlights Manufacturing Capacity To Attract Partnerships

Executive Summary

Biogen Idec plans to focus on licensing deals rather than mergers to grow its pipeline going forward, Executive VP-Business Development Mark Wiggins said during the company's analyst day Nov. 30
Advertisement

Related Content

Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B
Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005
Biogen Idec Deal Uses GSK Model; Partnerships To Double Pipeline By 2010
Biogen Idec Deal Uses GSK Model; Partnerships To Double Pipeline By 2010

Topics

Advertisement
UsernamePublicRestriction

Register

PS045049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel